CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $219,000 | +7.4% | 3,351 | 0.0% | 0.01% | +20.0% |
| Q2 2022 | $204,000 | -2.9% | 3,351 | 0.0% | 0.01% | +25.0% |
| Q1 2022 | $210,000 | +1.0% | 3,351 | +21.8% | 0.00% | 0.0% |
| Q4 2021 | $208,000 | -28.3% | 2,751 | +6.2% | 0.00% | -42.9% |
| Q3 2021 | $290,000 | -30.6% | 2,591 | +0.4% | 0.01% | -30.0% |
| Q2 2021 | $418,000 | +39.3% | 2,581 | +4.9% | 0.01% | +25.0% |
| Q1 2021 | $300,000 | -20.0% | 2,461 | +0.4% | 0.01% | -20.0% |
| Q4 2020 | $375,000 | -10.7% | 2,450 | -74.1% | 0.01% | -28.6% |
| Q3 2018 | $420,000 | +52.2% | 9,460 | -19.6% | 0.01% | +40.0% |
| Q4 2017 | $276,000 | – | 11,765 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |